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Background: Heart failure is a major cause of mortality and morbidity. As mortality rates are high, it is important
that patients seen by general practitioners with symptoms suggestive of heart failure are identified quickly and
treated appropriately. Identifying patients with heart failure or deciding which patients need further tests is a
challenge. All patients with suspected heart failure should be diagnosed using objective tests such as
echocardiography, but it is expensive, often delayed, and limited by the significant skill shortage of trained
echocardiographers. Alternative approaches for diagnosing heart failure are currently limited. Clinical decision tools
that combine clinical signs, symptoms or patient characteristics are designed to be used to support clinical
decision-making and validated according to strict methodological procedures. The REFER Study aims to determine
the accuracy and cost-effectiveness of our previously derived novel, simple clinical decision rule, a natriuretic
peptide assay, or their combination, in the triage for referral for echocardiography of symptomatic adult patients
who present in general practice with symptoms suggestive of heart failure.
Methods/design: This is a prospective, Phase II observational, diagnostic validation study of a clinical decision rule,
natriuretic peptides or their combination, for diagnosing heart failure in primary care. Consecutive adult primary
care patients 55 years of age or over presenting to their general practitioner with a chief complaint of recent new
onset shortness of breath, lethargy or peripheral ankle oedema of over 48 hours duration, with no obvious
recurrent, acute or self-limiting cause will be enrolled. Our reference standard is based upon a three step expert
specialist consensus using echocardiography and clinical variables and tests.
Discussion: Our clinical decision rule offers a potential solution to the diagnostic challenge of providing a timely
and accurate diagnosis of heart failure in primary care. Study results will provide an evidence-base from which to
develop heart failure care pathway recommendations and may be useful in standardising care. If demonstrated to
be effective, the clinical decision rule will be of interest to researchers, policy makers and general practitioners
worldwide.
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Heart failure (HF) is a life-threatening, costly condition
[1]. It affects at least 2.3% of adults over 45, rising to 4%
in over 75 year olds [2]. HF markedly reduces quality
and length of life [3], and treatment costs are high, sec-
ond only to stroke and mainly due to high admission
rates [4]; estimated to consume almost 2% (£751 million)
of total NHS expenditure [5]. HF is a diagnostic chal-
lenge, as symptoms are non-specific and physical signs
can be subtle [6-9]. Because outcomes in HF are linked
to stage of disease and evidence-based treatments alter
natural history as well as improve symptoms and prog-
nosis [10-12], accurate early diagnosis and treatment is
essential to reduce morbidity and mortality. As most
patients with suspected HF are seen initially by GPs
[6,13], the need for early and accurate diagnosis in pri-
mary care is essential to ensure optimum management
and appropriate treatment is initiated rapidly.
Specialist review of symptoms and signs plus objective
investigations, including echocardiography (Echo), is the
established ‘gold standard’ for diagnosing left ventricular
systolic dysfunction (LVSD) and increasingly suspected
HF with a preserved ejection fraction (HFpEF) [14].
Diagnosing HF requires objective estimation of cardiac
function (i.e. Echo) since determining the aetiology and
stage of HF leads to different management choices such
as initiation of angiotensin-converting enzyme (ACE)
inhibitors [10], ß-blockers [11] and aldosterone antago-
nists in most patients with LVSD [15], cardiac resyn-
chronization therapy for those with LVSD and broad
QRS complex [1], or surgery where significant valve dis-
ease exists. These therapies improve symptoms, progno-
sis and quality of life, and can reduce healthcare
utilisation and NHS costs. However, a difficulty is that
performing Echo on all suspected HF patients would be
costly as many patients are found not to have HF.
Diagnostic strategies can vary between GPs if a case of
HF is suspected, but the most appropriate strategy is un-
clear. These include an initial clinical assessment of pa-
tient signs and symptoms using physical examination,
and investigations such as lab blood tests or chest x-ray.
Additionally, screening tests, such as electrocardiogram
(ECG) and natriuretic peptide (NP) tests, where avail-
able, have been recommended by NICE as potential ‘rule
out’ tests for HF to limit unnecessary referrals to echo-
cardiography [16,17]. Routine clinical assessment takes
place over multiple consultations, due mainly to diag-
nostic uncertainty and delays that occur in the referral
pathway.
Diagnostic uncertainty in clinical practice, difficulties
diagnosing HF and local organisational factors such as lim-
ited availability of diagnostic services, or delays inherent in
the current referral system, create barriers to the early and
accurate diagnosis of HF. Access to Echo is variable, oftendelayed, and limited by the significant skill shortage of
trained Echocardiographers [14,16,18,19]. As a conse-
quence, many GPs rely solely on, often inaccurate, unstruc-
tured clinical assessment [7,8,18,20]. However, diagnosing
HF on clinical grounds alone can be unreliable due to diffi-
culty in interpreting signs [21] and differences between
doctors in obtaining symptoms and signs [13,22]. Many
GPs order a chest x-ray, or arrange an ECG [7]. However,
although a normal ECG will exclude LVSD in most cases,
changes may be subtle and lack of GP interpretation skills
may still require referral for specialist opinion. A normal
chest x-ray does not exclude HF [23]. A key dilemma facing
GPs is deciding which patients to refer for Echo and when;
and lack of a systematic method for guiding the diagnosis
of HF presents a further obstacle [7], adding to cost and
delay. Diagnostic uncertainty or inaccurate diagnosis can
result in diagnosis being delayed until HF symptoms are
more obvious and therefore more severe, multiple GP con-
sultations and hospital admissions, or people are treated
incorrectly.
A growing body of evidence suggests the potential util-
ity of B-type natriuretic peptides (NPs), namely BNP or
NT-proBNP, both released from myocardium in re-
sponse to wall stretch, as diagnostic cardiac biomarkers
of HF. These NP tests provide an exciting opportunity
to support the clinical assessment of symptomatic pri-
mary care patients, as normal levels can rule out HF
given the high sensitivity of these tests (98%) [24], but
confirmatory Echo is needed in patients with elevated
peptides to confirm the diagnosis [24-28].
There is uncertainty about the best cut-off levels of NPs
in primary care and the cost-effectiveness/benefit has not
been established. NP testing is under-used because reliable
data on BNP and NT-proBNP performance in the diagnosis
of HF are limited mainly to epidemiological sub-studies or
to prospective validation in emergency department settings
[27,29-31], with limited data on test performance within
symptomatic patients routinely presenting in primary care
[24,28,32]. Best assay cut-offs have therefore been largely
imputed and assay performance against or with ECG and
symptom score unclear. Moreover, obesity and certain HF
medications can lower peptide levels and elevated levels
can be associated with unrelated conditions and other fac-
tors such as increased age, gender and renal insufficiency
[25]. These factors therefore impair the utility of NPs as a
diagnostic marker of HF if used alone. The addition of a B-
type NP test to the current diagnostic pathway, with spe-
cialist referral if test results are abnormal, is a suggested
alternative approach that may be superior and cost-effective
[33]. However, the cost-effectiveness of NPs versus standard
diagnostic triage is not established.
Current consensus suggests a superior approach would
be to combine NP testing with standard clinical assess-
ment. In a recent prospective, randomised controlled
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onset breathlessness or oedema GP diagnoses were more
accurate with NT-proBNP test results in addition to
routine clinical assessment than without, mainly due to
the ability to correctly rule out HF [28]. A recent meta-
analysis concluded that the use of NPs could help reduce
the demand for Echo and cardiology referrals [34]. How-
ever, determining the optimal manner in which to com-
bine clinical features from clinical assessment and
diagnostic tests, including NP tests, remains extraordin-
arily challenging.
Clinical decision rules (CDRs) are evidence-based clin-
ical tools designed to be used to help clinician decision-
making in a standardised and cost-effective manner, and
are developed according to strict methodological pro-
cedure [35,36]. These clinical tools are based on a parsi-
monious set of variables that can quantify the
contribution from history, physical examination and
diagnostic tests. They are developed and evaluated in
three distinct stages prior to implementation into a clin-
ical setting: 1) creation of the rule, establishing the inde-
pendent and combined effect of explanatory variables
such as symptoms, signs or diagnostic tests; 2) validation
of the rule, establishing the accuracy and reliability of
the tool in a separate population; and 3) impact analysis
of the rule, establishing impact of applying the rule on
patient outcome or health professional behaviour.
A number of CDRs have been developed to diagnose
HF, using combinations of signs, symptoms and tests
[37-39]. However, a major problem with all the studies is
spectrum and referral bias since most were based on ob-
servational screening studies rather than symptomatic
presenting patients and some were hospital rather than
community based. Additionally, the tools are impractical
outside a research or emergency department setting as
they are based on a substantial number of variables;
others rely on clinical signs where there is considerable
inter-observer variation, even amongst specialists; and
others rely on chest x-ray parameters, which would be
difficult to apply in general practice.
Our recent NIHR HTA funded systematic review and
independent patient data and meta-analysis [40,41]
addressed this issue. We found individual symptoms
(such as breathlessness and fluid retention) and signs
(such as resting tachycardia and raised jugular venous
pressure) are generally weak predictors of HF. Both ECG
and BNP have high sensitivity for HF and are good tests
at ruling out the diagnosis but BNP is more accurate
than ECG. We found BNP and NT-proBNP to be of
similar accuracy.
Our systematic review [40] identified one unpublished
study which had developed a decision tool based on sim-
ple clinical features [42]. In our individual patient data
analysis [40,41] we further developed this tool andvalidated it on other primary care data sets. We found
that a simplified model, based upon simple clinical fea-
tures (Male gender, history of myocardial Infarction,
basal Crepitations, oEdema: ‘MICE’) and BNP derived
from one data set, was found to have good validity when
applied to other data sets, with the area under the curve
between 0.84 and 0.96, and reasonable calibration. A
model substituting ECG for BNP was less predictive.
Our systematic review concluded that BNP could substi-
tute for ECG for determining referral to Echo and some
patients could be referred with no prior tests on the
basis of clinical features alone.
We shall establish the clinical utility of B-type NP tests
in informing the diagnosis of diastolic HF as well as
LVSD and valve disease. Additionally, we shall determine
the probability thresholds of the CDR above which Echo
would be the most cost-effective diagnostic strategy, tak-
ing into account patient quality of life and survival. The
results will contribute to scientific progress by solving
the problem wherein GPs have clinical uncertainty about
whether an Echo should be done or not for a patient
whom they suspect may have HF. There is now an op-
portunity to provide these data and to potentially dem-
onstrate that the CDR can improve patient management
concerning diagnostic accuracy, clinical decision-making
and cost-effectiveness.
Our study will build upon the current evidence
and address the weaknesses in previous work. We
have validated the CDR on primary care data sets
but further validation in a symptomatic population
in the real-life clinical setting is now indicated. Fur-
ther exploration of the optimal NP cut-offs and fur-
ther modelling of cost-effectiveness is also needed.
We aim to prospectively validate the CDR in this
study but GPs will not apply the CDR (applying the
rule would be appropriate in an implementation
study); GPs will refer all patients suspected of having
HF and not previously diagnosed with Echo and we
shall collect data on how well the CDR predicts the
diagnosis of HF. The CDR’s impact potential will be
demonstrated by evaluating whether its sensitivity
and specificity is superior to that of GPs’ (unaided)
decisions. Given the risk of delayed diagnosis of HF,
GPs do not have clear guidance on whom to refer
for further evaluation. Improving the ability of GPs
to appropriately identify patients suspected of having
HF is crucial not only to avoid unnecessary hospital
admissions and reduce patient burden, but also to
improve the quality of care for patients presenting to
primary care with suspected HF.
We propose the following objectives:
1. To prospectively validate the performance of the
CDR and compare it to using a natriuretic peptide
Tait et al. BMC Cardiovascular Disorders 2012, 12:97 Page 4 of 12
http://www.biomedcentral.com/1471-2261/12/97assay alone on the diagnostic accuracy of HF in
primary care
2. To determine if the CDR, or natriuretic peptide assay
can be used in routine clinical practice to establish
referral on for echocardiography in patients
presenting with symptoms suggestive of HF
3. To quantify the most reliable cut-off levels of the
natriuretic peptide assay in a group of symptomatic
presenting patients
4. To model the cost-effectiveness of using the CDR in
primary care
Methods/design
Study design and setting
REFER is a prospective, observational, diagnostic validation
study of a CDR, natriuretic peptide or their combination,
for diagnosing heart failure in primary care. The study will
be conducted in 30 urban and rural primary care practices
in Birmingham, West Midlands, England.
Study population
All adult primary care patients aged 55 years or over
presenting to their GP with recent new onset symptoms
of breathlessness, lethargy or ankle oedema of over 48
hours duration, with no obvious recurrent, acute or self-
limiting cause will be enrolled.
Patient eligibility
Patient eligibility will be determined by the GP using in-
formation from clinical history and examination and
recording clinical judgment via a GP web-based database.
The eligibility criteria will be confirmed by investigation
and specialist interpretation of clinical assessments. Ob-
jective evidence of HF (reference standard) will be deter-
mined by a specialist panel that will validate previous
diagnosis and investigations.
Inclusion criteria
 All patients 55 years of age or over presenting to
their GP with new onset symptoms of
breathlessness, lethargy, or ankle oedema of over 48
hours duration, with no obvious recurrent, acute or
self-limiting cause
 Able to give informed consent
Exclusion criteria
Patients will be excluded if any of the following criteria
are met:
 Known pre-existing HF or LVSD of any cause.
However, patients with a pre-existing label of HF but
without objective evidence (i.e. echocardiography) of
this will not be excluded Severe symptoms requiring urgent assessment or
stabilisation (e.g. breathless at rest, hypotension,
confusion)
 Obvious clinically determined alternative diagnoses
such as chest infection, exacerbation of chronic
obstructive pulmonary disease or asthma
 Recent acute coronary syndrome (within 60 days)
 Major co-morbidity or other alternative diagnoses
of no obvious acute and self-limiting cause
(e.g. malignancy, severe respiratory disease, renal
dialysis, mental health problem)
 Unable to provide informed consent
Patient recruitment
GPs will give patients a written study information sheet
that outlines the nature of the study, including possible
benefits and risks, ethics approval, and advice that they
can decline to participate or withdraw at any time with-
out this affecting their medical care. GPs will then obtain
verbal consent; full informed written consent will be
taken subsequently by a research nurse at one of our
two research assessment clinics. The flow of patients
through the study is shown in Figure 1.
Referral of patients to research assessment clinics
GPs will refer all eligible patients who have given verbal
consent to participate in the study to one of our two re-
search assessment clinics in two ways by: 1) asking the
patient to telephone our research team administrator to
arrange an appointment within seven days of the initial
GP consultation, or the GP obtains patient contact
details for entry onto the GP electronic database and the
study team telephones the patient; and 2) GP completion
of eligibility criteria onto the web-based Case Report
Form will act as a referral letter, which we shall check to
confirm eligibility and to ensure that the patient has
contacted the research assessment team. If a patient
changes their mind between agreeing to participate at
the GP consultation and before attending their appoint-
ment at the research clinic, they are advised that they
can cancel by telephoning either the research team or
their GP. The patient can then re-consult with their GP,
if necessary. Patients who decline to take part in the
study will be managed as usual practice by GPs. When
eligible patients decline to participate in the study or
patients do not meet entry criteria for the study, GPs
will complete a weekly electronic notification form of
these details. These data will be used to assess potential
selection bias.
Recruitment rate
A total of 500 patients will be recruited, 25 per practice.
To allow for delays, the target recruitment rate will be
three patients per practice per month, with expected
Patients consented to the study
Chest x-ray (GP standard referral)
GP refers patient to research assessment 
clinic (within 7 days)
Primary Care Consultation
All patients presenting to GPs with symptoms suggestive of heart failure 
(i.e. new onset symptoms of breathlessness, lethargy or ankle oedema of 
over 48 hours duration) are eligible. 
GP screens patients for study eligibility
Baseline Clinical Information
1) GP records clinical information from history and 
examination
2) GP records their perceived referral or investigates 
decision as if this were routine care
Population
Patients age 55 or over presenting with symptoms suggestive of heart failure
Informed Consent: Verbal Consent 
taken by GP (n = 500)
Excluded patients
Pre-existing confirmed heart failure or LVSD
Severe symptoms requiring urgent 
assessment or stabilisation (e.g. breathless at 
rest, hypotension, confusion)
Obvious clinically determined alternative 
diagnoses (e.g. chest infection, exacerbation 
of COPD or asthma)
Recent acute coronary syndrome (within 60 
days)
Major co-morbidity or other alternative 
diagnoses of no obvious acute and self 
limiting cause
Inability to provide informed consent
Research Assessment Clinic
Written informed consent
History and clinical examination
ECG
Echocardiogram
Quality of life questionnaires (EQ-5D; SF12)
NT-proBNP
Creatinine
Additional Data Collection
(6 + 12 months)
Medical Note review of recruited patients
Follow-up Quality of Life questionnaires 
Reference Standard with estimation of any incorporation bias
Expert Consensus Panel (3 cardiology specialists):
Step 1: initially blinded to NT-proBNP results and CDR variables, will establish 
final diagnosis using the results of all the other clinical assessments (i.e. signs 
& symptoms, ECG, Echocardiogram, chest x-ray, creatinine, and Quality of life 
data). 
Step 2: CDR variables will then be made available to the panel and comparison 
made with initial diagnosis.
Step 3: NT-proBNP test results will be made available, and comparison made 
with initial diagnosis (the Reference Standard).
GP Review
Test results are fed back to GP for 
review and further action if required 
(e.g. referral to consultant care, 
initiation of medication) 
Figure 1 Flow of patient recruitment and data collection.
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monitor recruitment rates and if we fail to achieve the
target accrual rate, additional practices will be invited to
participate.
Clinical decision rule
The CDR, developed from our HTA individual patient
data and meta-analysis [40], intended to be used at the
start of the diagnostic pathway in primary care [43],
states:
Refer straight for echocardiography if the patient has
any one of:
 A history of Myocardial Infarction
 Basal crepitations Ankle oedema in a male
Otherwise, carry out a BNP (or NT-proBNP) test and
refer straight for echocardiography if BNP/NT-proBNP
level is above one of three cut-offs set by gender/symp-
toms recorded in the clinical rule:
 Female without ankle oedema, refer if BNP >
210-360 pg/ml depending upon local availability of
echocardiography (or NT-proBNP > 620-1060 pg/
ml), or
 Male without ankle oedema, refer if BNP >
130-220 pg/ml (or NT-proBNP > 390-660 pg/ml), or
 Female with ankle oedema, refer if BNP >
100-180 pg/ml (or NT-proBNP > 190-520 pg/ml).
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Primary outcomes include:
 Test performance of the CDR, estimating the
sensitivity and specificity, positive predictive value
and negative predictive value of the CDR for
diagnosis of HF in symptomatic patients presenting
with shortness of breath, lethargy, or ankle oedema
of over 48 hours duration
 Test performance of the diagnostic accuracy of NT-
proBNP for diagnosis of HF in symptomatic
patients, including sensitivity, specificity, positive
predictive value and negative predictive value
 Proportion of patients with LVSD or not (ejection
fraction <40%) and HF or not
Secondary outcomes include:
 Combination of the CDR and NT-proBNP
 Modelling of CDR test performance and
epidemiological data to ascertain the most cost
effective strategy in the diagnosis of HF in primary
care, incorporating data on quality of life (EQ-5D
and SF12 questionnaires), clinical events and health
care resource use
 Reliability of GP clinical judgment alone in
diagnosing HF
 Reliability of individual clinical features
 Reliability of ECG interpretation
 Estimation of the best performing cut-offs for NT-
proBNP to maximise diagnostic yield and for
maximizing cost-effective referrals
 Determine the use of variable echocardiographic
markers of diastolic function in the diagnosis of HF
with preserved ejection fractionClinical judgment
During the initial consultation, GPs will have identified a
patient as eligible for referral to one of the two research
assessment clinics (i.e. recent new onset shortness of
breath, lethargy or ankle oedema of over 48 hours dur-
ation). They will then complete the two clinical judgment
sections of the online web-based Case Report Form: 1)
details of symptoms, history and patient information, in-
cluding the predictive clinical features of the CDR; 2)
whether they would have made a clinical diagnosis of HF
or not and what they would have done routinely with this
patient (i.e. investigate, initiate referral, treat, follow-up).
Following diagnostic assessment at the research assess-
ment clinic, the NP results will be fed back to GPs and
based on those results, GPs will be asked what they would
do (refer or not refer to Echo) and if they would amend
their original diagnosis.Diagnostic assessment
The GP will have arranged for all patients to receive a
chest x-ray when verbally consenting patients for referral
(as is usual practice). Within seven days of referral, the
research assessment clinic team will obtain written
informed consent, collect baseline demographics, admin-
ister quality of life questionnaires (EQ-5D [44] and SF12
questionnaires [45]), clinically assess patients, perform
an ECG and echocardiogram, and take blood for NT-
proBNP, along with creatinine for a renal dysfunction
test, calculating an eGFR (serum profile). These clinical
assessments will be made by a research nurse or clinical
research fellow trained in these assessments, including
phlebotomy, auscultation and chest examination. The
heart sounds and chest sounds for each patient will be
recorded digitally and a random sample validated by a
Senior Cardiologist blinded to the assessment clinic find-
ings. If the research team believes an early decision on
management needs to be taken on the basis of the
patient’s symptoms or signs at the research assessment
clinic, or the results of any of the investigations, an ur-
gent specialist referral will be organised via the patient’s
GP. After we have received the GPs’ clinical judgment in
the Case Report Form on what they would do (refer or
not refer to Echo), all test results will be made available
to GPs.
ECG assessment and interpretation
A 12-lead electrocardiogram (ECG) will be performed.
ECGs will be analysed with diagnostic software and
double reported and interpreted by the Echocardio-
graphic Technician and a blinded consultant cardiolo-
gist, blinded to each other’s interpretation, the software
interpretation and other data (i.e. symptoms, echocardi-
ography, chest x-ray, NT-proBNP results). Inter-
observer variability will be recorded and analysed.
Echocardiographic assessment
Echocardiography will be performed within seven days
of GP referral by a BSE Accredited Echocardiography
Technician, using a portable high-quality Vivid i Ultra-
sound machine. The echocardiographic assessment, with
objective assessment of left ventricular dimensions and
ejection fraction, measurement by an area-length
method, will be extended to include assessment of dia-
stolic dysfunction. Echocardiogram results, together with
clinical assessment results, will be used to establish the
final diagnosis, as the reference standard.
Questionnaire measures
The quality of life questionnaires will be self-
administered in the research clinic and data entered into
an electronic database. Follow-up questionnaires will be
mailed to patients at 6 and 12 months to provide data
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pants with the Office of Population & Census Statistics
(OPCS), based on our previous studies (e.g. Echoes-X),
and the research team will check patient status (dead/
alive) before sending follow-up questionnaires to
patients.
The EuroQol 5D (EQ-5D) questionnaire
The EQ-5D is a widely used patient-based generic ques-
tionnaire for self perceived health assessment [44]. There
are five domains, including mobility, self care, main ac-
tivity (i.e. work), leisure activity, pain and anxiety. It
describes health-related quality of life, giving a single
index score for each health state measured that can be
combined to generate a single index where 1 = perfect
health and negative scores represent poorer states of
health.
SF-12 questionnaire
The SF-12 is a widely used and validated short generic
questionnaire for measuring health related QoL [45],
and has been validated for measuring QoL of patients
with cardiovascular disease [46].
Blood collection and biomarker assessment
We shall collect a 30ml blood sample by venepuncture
into EDTA K2 blood tubes to perform a point of care
NT-proBNP test using a Cobas h 232 Reader and Roche
Diagnostics CARDIAC proBNP test strips, for immedi-
ate results, and to perform a serum creatinine test to ex-
clude renal dysfunction and calculate an eGFR (serum
profile). Blood samples will be sent to Midlands Path-
ology for spinning and storage for batch analysis, and
stored at −80°C for future analysis.
Reference standard for presence/absence of heart failure
An independent expert consensus panel comprising
three cardiology specialists will determine the final diag-
nosis of LVSD or not (ejection fraction <40%) and HF or
not, based on internationally accepted definition [47],
with differences resolved by consensus. In order to reach
an accurate diagnosis the consensus panel need all clin-
ical and test information but this could introduce in-
corporation bias. To minimise this but provide fuller
information for the consensus panel they will receive in-
formation in 3 steps. In Step 1, echocardiography results
will be provided along with all other clinical information
except the NT-proBNP test results and clinical variables
included in the CDR, namely, history of myocardial in-
farction, gender, basal lung crepitations and ankle
oedema. The consensus panel will reach a decision on
whether or not heart failure is present initially without
these data. In Step 2, CDR clinical variables will then be
made available to the expert panel and comparison madewith the initial assessment. In Step 3, NT-proBNP test
results will be provided and the consensus panel asked
whether this changes their opinion. The primary refer-
ence standard for the study is therefore Step 3 where all
clinical and test information is available to the consensus
panel. However, we will also be able to accurately esti-
mate any incorporation bias that may have related to
this reference standard based upon Steps 1 and 2.
Definition of heart failure
Clinical HF will be defined using the European Society
of Cardiology guidelines: “HF is a syndrome in which
the patients should have the following features: symp-
toms and signs of HF and objective evidence of an ab-
normality of the structure or function of the heart at
rest” [14].
Medical note review
Medical note review, obtained from GP notes, on
recruited patients will be performed at 6 and 12 months.
Data on medications, hospital and nursing home admis-
sions, A&E attendance, referrals presentation with new
symptoms/complications and death will be recorded.
We shall use these data (i.e. clinical events and resource
use) in the economic modelling of outcomes associated
with the use of the CDR.
Sample size
Thirty urban and rural general practices in the West
Midlands will be asked to participate to recruit 500
symptomatic patients. A search of routine practice mor-
bidity data suggest that in a practice of 6,000 patients,
around 60 patients over age 55 per year will present with
new onset breathlessness. Breathlessness is the common-
est of the three most likely symptoms of heart failure
(others are lethargy or ankle swelling) and therefore
these estimates on the rate that symptoms present will
be the minimum rates. Assuming a 60% response rate
then it would take at least nine months to recruit at least
25 such patients per practice. All practices will stop ac-
tive patient recruitment at the end of 18 months. Calcu-
lations are based on sensitivity of 94% and specificity of
48% obtained from application of the CDR in our HTA
funded individual patient data meta-analysis [40] and
the prevalence of heart failure in a symptomatic popula-
tion of 30%. A sample size of 500 patients with HF
symptoms will therefore be sufficient to estimate the
sensitivity of the CDR to within 4% and specificity to
within 6% at the 95% confidence level.
Statistical analysis
Data will be analysed using SAS and STATA software.
Patients with symptoms of HF that are referred to Echo
via the CDR will be classed as Test disease present and
Tait et al. BMC Cardiovascular Disorders 2012, 12:97 Page 8 of 12
http://www.biomedcentral.com/1471-2261/12/97the remaining patients classed as Test disease absent.
The Observed disease present or absent will be deter-
mined by the expert panel following Echo and other
clinical assessments. Crosstabulation of Test versus
Observed disease status will enable calculation of sensi-
tivity (true positive rate), specificity (true negative rate),
positive predictive value (PPV: proportion with a positive
test result who actually have the target condition), nega-
tive predictive value (NPV: proportion with a negative
test result who do not have the target condition), and
likelihood ratios for testing the performance of the CDR.
95% confidence intervals for these performance statistics
will be calculated using the binomial exact method.
To confirm whether the NT-proBNP cut-offs in the
CDR are optimal in the real life clinical setting, an add-
itional ROC curve analysis of NT-proBNP to predict HF
will be performed. Analysis will compare the CDR per-
formance against the step 1 reference test alone; against
the step 1 reference test plus clinical features of the
CDR (step 2); and against the step 1 reference test plus
the CDR and the NT-proBNP result (the reference
standard, step 3). Step 3 is the primary reference stand-
ard for analysis. This will allow us to: 1) quantify the
effects of any incorporation bias; 2) explore the impact
that availability of NT-proBNP test result would have on
the reference standard diagnosis of HF. Comparison of
the GPs’ and researcher’s clinical findings (lung crepita-
tions, ankle oedema, decision to refer to Echo) will be
assessed by the kappa statistic. Logistic regression will
be used to identify which diastolic parameters of echo-
cardiography are independently associated with the diag-
nosis of heart failure with preserved ejection fraction.
Health economic analysis
A decision tree will be used to assess the cost-
effectiveness of the CDR [48]. The prevalence of heart
failure in patients presenting to primary care will be
determined both from the study cohort and from a re-
view of the epidemiological literature. The probability
that patients with and without heart failure will be re-
ferred for echocardiography will be determined based on
the test characteristics of both the CDR and of existing
practice. The decision tree may be further refined de-
pending on the power of the available data from the
study; for example, distinguishing between patients with
HF of different levels of severity (such as LVSD and
HFpEF patients).
Cost and quality of life implications for patients at dif-
ferent branches of the decision tree will be extrapolated
based both on data collected during the study and from
the literature. Prospectively collected data on quality of
life, clinical events and health care resource use will be
used to estimate outcomes associated with using the
CDR, NT-proBNP, their combination, or continuingwith current practice. Since the study does not capture
the full details of every acute event in the cohort, the
cost and quality of life implications of such events will
be imputed from the literature and standard UK sources
of health economic information [49,50].
Outcomes associated with current practice will be esti-
mated by using GP reported clinical judgment to predict
their intentions for patients in the absence of using the
CDR. In addition, the model will allow exploration of
the effect on cost effectiveness of hypothetical scenarios
involving altering the threshold peptide value for referral
to echocardiography. Decreasing the threshold will cause
more people to be referred for echocardiography, hence
increasing costs but also improving outcomes. By using
a suitable threshold cost per QALY cut-off (such as
the threshold of £20,000 - £30,000 used by the National
Institute of Health and Clinical Excellence) [51], the
optimal threshold peptide value for referral can be
estimated [52].
Costs will be evaluated from a health care provider
perspective, with a lifetime time horizon. The effect of
uncertainty in parameter values will be quantified by
both univariate and probabilistic sensitivity analysis,
and will be summarised using appropriate methods
(cost-effectiveness plots and/or cost-effectiveness ac-
ceptability curves) [48].
Ethical considerations
The study has full approval from South Birmingham Research
Ethics Committee, reference number 09/H1207/121. We shall
ensure that participation in the study does not lead to inferior
medical care by performing the diagnostic assessments within
seven days of GP referral and by informing the patient’s GP of
the clinical assessment results and any clinical abnormalities
uncovered within seven days. Therefore, study patients will
receive a higher standard of care than would be likely in rou-
tine practice. Post-study medical care will be provided by
patients’ GPs.
Participant consent
We shall ensure that patients are fully informed about
all aspects of the study prior to obtaining informed con-
sent. Study duration, assessments and the voluntary na-
ture of participating will be discussed before obtaining
written informed consent. We shall record all requests
to withdraw from the study.
Potential risks and burdens
There should be no risk to patients since a full diagnos-
tic assessment, including the reference standard diagno-
sis, which is non-invasive, is carried out on all patients
in the study and in a timely manner. Therefore, patients
are receiving a higher standard of care than would be
likely in routine practice.
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The data manager will oversee all data collection with
built in validation and regular reports to ensure the in-
tegrity of data. The database will be monitored exclu-
sively by the data manager and the statistician. Data will
be extracted from the database and imported into statis-
tical software packages, SAS and STATA. The statistician
will then perform further validation checks through ex-
ploratory data analysis, identifying any blank fields, out-
liers and logical inconsistencies between fields. Any
problems detected will be then verified and corrected by
the data manager. The project manager will ensure that
the conduct of the study complies with the currently
approved protocol, with Good Clinical Practice, and all
applicable R&D regulatory procedures. All study activ-
ities will be performed in accordance with the University
of Birmingham Standard Operating Procedures.
Research governance
The study will be conducted in accordance with the
Guidelines for Good Clinical Practice, the Research Gov-
ernance Framework for Health and Social Care, 2005
and the Data Protection Act 1998. Patient involvement
has ensured that both the patient information and con-
sent forms are relevant to the patients the study
attempts to improve services for. All relevant regulatory
approvals have been sought prior to commencing the
study and the study registered with the UK Clinical Re-
search Network (UKCRN No: 7944). We have obtained
ISRCTN registration (ISRCTN17635379) prior to patient
enrolment.
The study will be conducted in compliance with Data
Protection legislation, with particular attention given to the
emphasis on privacy and on processing of personal data
extending to disposal or destruction and disclosure to a
third party. Participants shall be informed that information
may be accessed during the study by Regulatory Authorities
or the relevant NHS Trust in compliance with the Data
Protection legislation. Data processing and linkage of per-
sonal information will be subject to the strictest ethical
safeguards of anonymity, with documents assigned a nu-
merical code. All data shall be held securely and treated
with the strictest confidentiality.
Indemnity and sponsorship
The University of Oxford has arrangements in place to
provide for negligent and non-negligent harm arising
from participation in the study for which the University
is the Research Sponsor. NHS indemnity operates in re-
spect of the clinical treatment which is provided.
Role of the funding source
The funders have no involvement in the following activ-
ities: study design; collection, analysis or interpretationof data; report writing or submission of manuscripts for
publication.
Discussion
The REFER Study is a multicentre, Phase II study
designed to prospectively validate a CDR to improve the
diagnosis of heart failure in primary care. HF is a diag-
nostic dilemma for the general practitioner [6,8,13,53].
In the absence of an accurate method of identifying
patients with HF, triage of patients for echocardiography
in primary care is variable. As a result HF diagnosis is
often delayed, misdiagnosed, or treated incorrectly [53].
The main characteristic of the REFER study is that it
examines a symptomatic adult population presenting in
general practice.
A major problem with all the studies we uncovered in
our review of the diagnostic test systematic reviews is
spectrum and referral bias since most were based on
observational screening studies rather than symptomatic
presenting patients, and some were hospital rather than
community based [40]. Only a prospective study design
with consecutively recruited symptomatic patients can avoid
or minimise these potential biases. Another major strength
of the REFER study is that the study has been designed
according to strict methodological standards to determine
the diagnostic accuracy of the CDR [35,43,54-56]. Moreover,
the study’s design will provide data on the impact of the
availability of the NT-proBNP result on the reference stand-
ard diagnosis of heart failure. These data are of clinical sig-
nificance, given that the current NICE algorithm for heart
failure diagnosis envisages NT-proBNP being used princi-
pally as a triage test to determine which patients should
have echocardiography [16]. However, in diagnosis of heart
failure with preserved ejection fraction, it may be that a
raised natriuretic peptide level is of diagnostic value in its
own right. Further, the results will provide data on optimum
natriuretic peptide cut-offs which, as far as we are aware,
are not yet available. Additionally, the planned modelling
will indicate whether further research is not necessary if the
strategy dominates or the technology fails. An intermediate
result would enable accurate powering for any future Phase
III trial.
Limitations
This study has potential limitations that apply to valid-
ating CDRs. Reference standard misclassification is an
inherent problem of diagnostic accuracy studies that
may introduce bias [57,58]. The prospective study de-
sign will allow us to ensure that all symptomatic
patients presenting with new onset symptoms suggest-
ive of heart failure will receive identical standardised
assessments.
This will ensure that all patients are diagnosed in a
consistent manner in order to avoid introducing
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standard also incorporates multiple assessments, thereby
minimising potential reference standard misclassification
[59]. Another possible limitation concerns incorporation
bias. This occurs when knowledge of the result of the
index test influences the reference standard test. The
CDR incorporates variables from the history, examin-
ation and tests that would normally be included in a
reference standard. To minimise the potential for bias
our expert consensus panel will initially receive the clin-
ical information and investigation results about the pa-
tient with the exception of the information that
comprises the CDR (namely history of myocardial in-
farction; gender; basal lung crepitations and ankle
oedema) and the NT-proBNP result. They will be asked
to reach a decision on whether or not HF is present ini-
tially without these data. They will then be given the
clinical features of the CDR score and asked if this influ-
ences their decision, and then the results of the NT-
proBNP test. This stepped reference standard will allow
us to quantify the effects of any incorporation bias.
Selection bias is a key issue in diagnostic accuracy
studies. This bias would occur if GPs enrolled only those
patients they believed to have a high probability of heart
failure. This would mean more symptomatic or more se-
vere cases would dominate the study sample and result
in an over-estimation of the test-accuracy of the CDR
[57,58]. In our study, the consecutive inclusion of all
symptomatic patients will minimise the risk of introdu-
cing this type of bias. GPs will be asked to refer all
patients over 55 years of age presenting with the target
symptoms regardless of whether or not heart failure is
suspected by the doctor and excluding patients with pre-
existing confirmed heart failure. Verification bias is also
a potential limitation and may occur if patients with low
pre-test probability of heart failure were to be excluded
from undergoing reference standard diagnostic testing to
verify the diagnosis of heart failure. This would result in
an over-estimation of test sensitivity [58]. Performing all
diagnostic assessments on all patients included in the
study will minimise this potential source of bias.Conclusions
We aim to prospectively validate our previously derived
(Phase I) novel, simple CDR in a new set of symptomatic
patients in clinical practice. If shown to be cost-effective,
the CDR will support GPs in prioritising which patients
with symptoms suggestive of HF should be referred on
for echocardiography. The CDR has the potential to im-
prove patient care and GP clinical decision-making, re-
duce diagnostic uncertainty and variability in practice,
increase the speed with which people with HF com-
mence treatment, and lower NHS costs.Publication policy and dissemination
Recommended practice in journal guidelines will be fol-
lowed in relation to authorship. We shall comply with
authorship guidelines suggested by the International
Committee of Medical Journal Editors, available at
http://www.icmje.org.
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